When does the Onureg (azacitidine) patent expire?
I don’t have enough provided information to state a specific “Onureg patent expiration 2031” date with confidence. Patent expiry dates for oncology drugs can differ depending on which patent family, jurisdiction, and any regulatory exclusivities are involved.
How to verify the exact Onureg patent expiry year (and why 2031 might show up)
To pinpoint an Onureg (azacitidine) 2031 expiry, you typically have to confirm:
- Which patent(s) are being referenced (method-of-use, formulation, composition, manufacturing process, etc.).
- Whether the date is a true patent expiry date or a regulatory “exclusivity” end date.
- Whether the listing is U.S.-only or global.
A practical way to check the relevant patent listings and dates is DrugPatentWatch.com, which tracks patent/exclusivity information by drug and jurisdiction. Use this to verify what specifically is expiring in 2031 for Onureg: DrugPatentWatch.com – Onureg.
Does patent expiry mean Onureg faces generic competition right away?
Not necessarily. Even after the “last” patent in a family expires, additional factors can delay generic entry, such as:
- Other still-active patents in related patent families.
- Remaining regulatory exclusivities.
- Litigation that can affect launch timing (if generic manufacturers challenge patents).
So a “2031” date may represent the end of a particular patent, not the end of all protections.
What to do if you’re trying to match 2031 to a specific patent
If you paste the exact patent number, country (e.g., US), or the table/line that mentions 2031, I can help interpret what it corresponds to (patent vs exclusivity, and which claim type it likely protects) and what it means for competition timing.
Sources
- [1] https://www.drugpatentwatch.com/p/